HERIZON-BTC-01

Update 28 April, 2022. Zymeworks have announced that as enrolment to the HERIZON-BTC-01 trial has completed, the trial is now closed to recruitment.  It is expected that efficacy and safety results will be available early 2023. To read the Zymeworks’ press release, click here.

A Phase 2b, Open-label, Single-arm Study of Zanidatamab ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers

HERIZON-BTC-01 is a global Phase 2b study of Zanidatamab (also known as ZW25) for the treatment of patients with advanced or metastatic HER2-amplified biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer.

This multi-centre trial is currently open and recruiting at the following UK locations:

  • Hammersmith Hospital, London (Imperial College) – Dr Harpreet Wassan
  • Royal Free London – Dr Roopinder Gillmore
  • University College Hospital, London – Professor John Bridgewater

For more information, including other European and other locations, please see:
https://clinicaltrials.gov/ct2/show/NCT04466891

Sponsors and collaborators:
Zymeworks Inc.
BeiGene, Ltd.

Back to previous page